Licensing Opportunities

Chimerix has raised sufficient funds to develop drug candidates through proof of concept clinical trials and plans to partner with pharmaceutical companies for late stage clinical trials, distribution, and marketing.

The Chimerix ProLipTagTM technology is broadly enabling and the company anticipates expanding application to other therapeutic areas through collaborations and licensing agreements. Chimerix is seeking partners to apply Chimerix technology through any of the following mechanisms:

  • Licensing or co-development of Chimerix drug candidates and lead compounds
  • Collaborations to apply the Chimerix technology to lead compounds or drug candidates identified by a partner that have ADME limitations or require intracellular delivery
  • Drug discovery collaborations applying Chimerix technology to new chemical classes that have not been amenable to pharmaceutical development in the past

For more info please contact busdev@chimerix-inc.com

Latest News

April 1, 2008

Potential wonder drugs - Chimerix article in The New Economy

[more]

January 29, 2008

Merial to Screen Chimerix’ Chemical Library for Animal Health Drug Leads

[more]

read all news

Next Event

April 18, 2008 - Chimerix to present at 25th Annual Venture Conference

Chimerix company overview

[more]

June 10, 2008 - Chimerix to present at XVII International HIV Drug Resistance

Hexadecyloxypropyl tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile

[more]